UTRS (Minerva Surgical) YoY EBITDA Growth: 90.55% (As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Minerva Surgical YoY EBITDA Growth?

Minerva Surgical UTRS YoY EBITDA Growth is 90.55% as of Sep. 2023.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Minerva Surgical's YoY EBITDA Growth for the quarter that ended in Sep. 2023 was 90.55%.

Minerva Surgical's EBITDA per Share for the three months ended in Sep. 2023 was $-0.51.

Minerva Surgical YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Minerva Surgical's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Minerva Surgical YoY EBITDA Growth Chart

Minerva Surgical Annual Data
Trend Dec19 Dec20 Dec21 Dec22
YoY EBITDA Growth
0.00 102.28 216.02 -647.96

Minerva Surgical Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -358.83 -116.52 69.99 59.76 90.55

Minerva Surgical YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Minerva Surgical's YoY EBITDA Growth for the fiscal year that ended in Dec. 2022 is calculated as:

YoY EBITDA Growth (A: Dec. 2022 )
=(EBITDA per Share (A: Dec. 2022 )-EBITDA per Share (A: Dec. 2021 ))/ | EBITDA per Share (A: Dec. 2021 ) |
=(-13.94-2.544)/ | 2.544 |
=-647.96 %

Minerva Surgical's YoY EBITDA Growth for the quarter that ended in Sep. 2023 is calculated as:

YoY EBITDA Growth (Q: Sep. 2023 )
=(EBITDA per Share (Q: Sep. 2023 )-EBITDA per Share (Q: Sep. 2022 )) / | EBITDA per Share (Q: Sep. 2022 )) |
=(-0.514--5.438)/ | -5.438 |
=90.55 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 90.55% mean?
Minerva Surgical (UTRS) has a YoY EBITDA Growth of 90.55% as of Sep. 2023. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Minerva Surgical and its competitors.
Is Minerva Surgical's YoY EBITDA Growth too high?
Minerva Surgical's current YoY EBITDA Growth is 90.55%.
How does Minerva Surgical's YoY EBITDA Growth compare to PAVM and ELUT?
Minerva Surgical's YoY EBITDA Growth of 90.55% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Medical Devices & Instruments company?
A good YoY EBITDA Growth depends on the Medical Devices & Instruments industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Minerva Surgical and its competitors. Minerva Surgical's current YoY EBITDA Growth is 90.55%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minerva Surgical stock overvalued right now?
Minerva Surgical (UTRS) has a current YoY EBITDA Growth of 90.55%. The current YoY EBITDA Growth is 90.55%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Minerva Surgical (UTRS), the current YoY EBITDA Growth is 90.55% as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Minerva Surgical Business Description

Address 4255 Burton Drive, Santa Clara, CA, USA, 95054
Minerva Surgical Inc is a medical device company that develops therapeutic devices that treat abnormal uterine bleeding in a minimally invasive manner. The Company operates and manages its business as one reportable and operating segment, which is the business of research, development, and sale of therapeutic devices for abnormal uterine bleeding treatment.